In­novent says next-gen GLP-1 drug from Lil­ly beats top di­a­betes med in Phase 3 Chi­na study

A next-gen­er­a­tion GLP-1 can­di­date from Eli Lil­ly has out­done an old­er Lil­ly drug in a Phase 3 tri­al in­volv­ing Chi­nese pa­tients with di­a­betes, Lil­ly part­ner …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER